Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes

Life Sciences

Volumn 74, Issue 22, 2004, Pages 2769-2779

  Kim, Kyoung Ah ^a   Lee, Ji Suk ^a   Park, Hi Joon ^a   Kim, Jin Woo ^a   Kim, Chang Ju ^a   Shim, In Sop ^a   Kim, Nam Jae ^a   Han, Seung Moo ^a   Lim, Sabina ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Cytochrome P450; Herbal medicine; Microsomes; Oleanolic acid; Ursolic acid

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; MEPHENYTOIN; MIDAZOLAM; OLEANOLIC ACID; PHENACETIN O DEETHYLASE; TRITERPENE DERIVATIVE; URSOLIC ACID;

ARTICLE; CATALYSIS; CATALYST; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EXPERIMENTAL TEST; HUMAN; HUMAN TISSUE; HYDROXYLATION; IC 50; LIVER MICROSOME; LIVER PROTECTION;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; MICROSOMES, LIVER; PLANT PREPARATIONS; TRITERPENES;

EID: 1642314458     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.10.020     Document Type: Article

References (41)

1. Alvarez M.E., Maria A.O., Saad J.R. Diuretic activity of Fabiana patagonica in rats. Phytotherapy Research. 16:2002;71-73.
2. Baricevic D., Sosa S., Della Loggia R., Tubaro A., Simonovska B., Krasna A., Zupancic A. Topical anti-inflammatory activity of Salvia officinalis L. leaves: the relevance of ursolic acid. Journal of Ethnopharmacology. 75:2001;125-132.
3. Broly F., Libersa C., Lhermitte M., Bechtel P., Dupuis B. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. British Journal of Clinical Pharmacology. 28:1989;29-36.
4. Chang J. Medicinal herbs: drugs or dietary supplements. Biochem. Pharmacol. 59:2000;211-219.
5. Es-saady D., Simon A., Ollier M., Maurizis J.C., Chulia A.J., Delage C. Inhibitory effect of ursolic acid on B16 proliferation through cell cycle arrest. Cancer Letters. 106(2):1996;193-197.
6. Flockhart D.A. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clinical Pharmacokinetics. 29(suppl. 1):1995;45-52.
7. Guengerich F.P., Kim D.H., Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology. 4:1991;168-179.
8. Guengerich F.P., Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology. 4:1991;391-407.
9. Guengerich F.P., Shimada T., Iwasaki M., Butler M.A., Kadlubar F.F. Activation of carcinogens by human liver cytochromes P-450. Basic Life Sciences. 53:1990;381-396.
10. Harris J.W., Rahman A., Kim B.R., Guengerich F.P., Collins J.M. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Research. 54:1994;4026-4035.
11. He K., Iyer K.R., Hayes R.N., Sinz M.W., Woolf T.F., Hollenberg P.F. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chemical Research in Toxicology. 11:1998;252-259.
12. Jeong H.G. Inhibition of cytochrome P450 2E1 expression by oleanolic acid: hepatoprotective effects against carbon tetrachloride-induced hepatic injury. Toxicology Letters. 105:1999;215-222.
13. Jeong T.S., Hwang E.I., Lee H.B., Lee E.S., Kim Y.K., Min B.S., Bae K.H., Bok S.H., Kim S.U. Chitin synthase II inhibitory activity of ursolic acid, isolated from Crataegus pinnatifida. Planta Medica. 65:1999;261-263.
14. Kashiwada Y., Nagao T., Hashimoto A., Ikeshiro Y., Okabe H., Cosentino L.M., Lee K.H. Anti-AIDS agents 38. Anti-HIV activity of 3-O-acyl ursolic acid derivatives. Journal of Natural Products. 63:2000;1619-1622.
15. Kent U.M., Aviram M., Rosenblat M., Hollenberg P.F. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metabolism and Disposition. 30:2002;709-715.
16. Kim K.A., Park J.Y. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes. Drug Metab. Dispos. 31:2003;1090-1092.
17. Li Y., Matsuda H., Yoshikawa M. Effects of oleanolic acid glycosides on gastrointestinal transit and ileus in mice. Bioorganic and Medicinal Chemistry. 7:1999;1201-1205.
18. Liu J., Liu Y., Madhu C., Klaassen C.D. Protective effects of oleanolic acid on acetaminophen-induced hepatotoxicity in mice. The Journal of Pharmacology and Experimental Therapeutics. 266:1993;1607-1613.
19. Liu J., Liu Y., Parkinson A., Klaassen C.D. Effect of oleanolic acid on hepatic toxicant-activating and detoxifying systems in mice. The Journal of Pharmacology and Experimental Therapeutics. 275:1995;768-774.
20. Lucas D., Menez J.F., Berthou F. Chlorzoxazone: and in vitro and in vivo substrate probe for liver CYP2E1. Methods Enzymology. 272:1996;115-123.
21. Ma C., Nakamura N., Hattori M., Kakuda H., Qiao J., Yu H. Inhibitory effects on HIV-1 protease of constituents from the wood of Xanthoceras sorbifolia. Journal of Natural Products. 63:2000;238-242.
22. Marquina S., Maldonado N., Garduno-Ramirez M.L., Aranda E., Villarreal M.L., Navarro V., Bye R., Delgado G., Alvarez L. Bioactive oleanolic acid saponins and other constituents from the roots of Viguiera decurrens. Phytochemistry. 56:2001;93-97.
23. Nebert D.W., McKinnon R.A., Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA and Cell Biology. 5:1996;273-280.
24. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. The Journal of Pharmacology and Experimental Therapeutics. 294:2000;88-95.
25. Omiecinski C.J., Remmel R.P., Hosagrahara V.P. Concise review of the cytochrome P450s and their roles in toxicology. Toxicological Sciences. 48:1999;151-156.
26. Park J.Y., Kim K.A. Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 59:2003;407-409.
27. Porter T.D., Coon M.J. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. Journal of Biological Chemistry. 266:1991;13469-13472.
28. Raucy J.L. Risk assessment: toxicity from chemical exposure resulting from enhanced expression of CYP2E1. Toxicology. 105:1995;217-224.
29. Rendic S., Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews. 29:1997;413-580.
30. Rettie A.E., Korzekwa K.R., Kunze K.L., Lawrence R.F., Eddy A.C., Aoyama T., Gelboin H.V., Gonzalez F.J., Trager W.F. Hydroxylation of S-warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of S-warfarin-drug interactions. Chemical Research in Toxicology. 5:1992;54-59.
31. Saraswat B.S., Visen P.K.S., Dayla R., Agarwal D.P., Patnaik G.K. Protective action of ursolic acid against chemical induced hepato-toxicity in rats. Indian Journal of Pharmacology. 28:1996;232-239.
32. Saraswat B., Visen P.K., Agarwal D.P. Ursolic acid isolated from Eucalyptus tereticornis protects against ethanol toxicity in isolated rat hepatocytes. Phytotherapy Research. 14:2000;163-166.
33. Schmiedlin-Ren P., Edwards D.J., Fitzsimmons M.E., He K., Lown K.S., Woster P.M., Rahman A., Thummel K.E., Fisher J.M., Hollenberg P.F., Watkins P.B. Mechanism of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metabolism and Disposition. 25:1997;1228-1233.
34. Shin J.G., Park J.Y., Kim M.J., Shon J.H., Yoon Y.R., Cha I.J., Lee S.S., Oh S.W., Kim S.W., Flockhart D.A. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome p450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metabolism and Disposition. 30:2002;1102-1107.
35. Sohn K.H., Lee H.Y., Chung H.Y., Young H.S., Yi S.Y., Kim K.W. Anti-angiogenic activity of triterpene acids. Cancer Letters. 94:1995;213-218.
36. Tanaka E., Terada M., Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. Journal of Clinical Pharmacy and Therapeutics. 25:2000;165-175.
37. Tang H.Q., Hu J., Yang L., Tan R.X. Terpenoids and flavonoids from Artemisia species. Planta Medica. 66:2000;391-393.
38. Tassaneeyakul W., Birkett D.J., Veronese M.E., McManus M.E., Tukey R.H., Quattrochi L.C., Gelboin H.V., Miners J.O. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. The Journal of Pharmacology and Experimental Therapeutics. 265:1993;401-407.
39. Thummel K.E., Shen D.D., Podoll T.D., Kunze K.L., Trager W.F., Hartwell P.S., Raisys V.A., Marsh C.L., McVicar J.P., Barr D.M., Perkins J.D., Cariers R.L. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. The Journal of Pharmacology and Experimental Therapeutics. 271:1994;549-556.
40. Wrighton S.A., Stevens J.C., Becker G.W., Vandenbranden M. Isolation and characterization of human cytochrome P4502C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Archives of Biochemistry and Biophysics. 306:1993;240-245.
41. Yoshikawa M., Matsuda H. Antidiabetogenic activity of oleanolic acid glycosides from medicinal foodstuffs. Biofactors. 13:2000;231-237.